Uveitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Uveitis is a broad term that refers to a group of inflammatory diseases that cause swelling and destroy eye tissues. These diseases can cause minor vision loss or severe vision loss.
·
According to one estimate, chronic,
non-infectious posterior uveitis affects 175,000 people in the United States
and 800,000 people worldwide.
Thelansis’s “Uveitis Market Outlook,
Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Uveitis treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Uveitis across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Uveitis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment